Compare Crispr Therapeutics AG (CRSP) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs NetApp Inc. — how do they compare? Crispr Therapeutics AG trades at $51.49 (market cap $4.97B), while NetApp Inc. trades at $162.11 (market cap $34.20B). The key difference: NetApp Inc. is far larger — about 6.9× Crispr Therapeutics AG's market cap, and NetApp Inc. pays a 1.19% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NTAP | |
|---|---|---|
Market Cap | $4.97B | $34.20B |
Sector | Health | Technology |
52-Week High | $76.78 | $181.08 |
52-Week Low | $44.34 | $94.11 |
Enterprise Value | $3.32B | $33.35B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
NetApp (NTAP) trades at $163.93, down 2.93% on the day, but maintains a bullish technical stance with strong moving averages and support near $162. The company demonstrates robust fundamentals with a 70.74% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.43 versus $2.27 expected. Recent news highlights AI-driven growth opportunities, such as StorageGRID 12.1 enhancements for AI workloads announced on June 23, 2026.
Outlook remains positive with analyst consensus target at $167.45, offering modest upside. Key opportunities include enterprise AI demand and all-flash storage adoption, while risks involve competitive pressures and debt levels rising to 29.89% of assets. The stock's valuation at a P/E of 25.82 warrants monitoring amid sector comparisons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
